CORPORATE PRESENTATION January 2019 ADVANCING CARDIOVASCULAR AND NASH OPPORTUNITIES Exhibit 99.1

Safe Harbor Statement This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward‐looking statement. In some cases, you can identify forward‐looking statements by terminology such as “may”, “will”, “could”, “would”, “should”, “plan”, “predict”, “potential”, “project”, “promising,” “expect,” “estimate,” “anticipate,” “intend,” “goal,” “strategy,” “believe,” “milestone,” and similar expressions and variations thereof. Forward‐looking statements may include statements regarding the Company’s business strategy, market size, potential growth opportunities, capital requirements and use of proceeds, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the product candidate. Although the Company believes that the expectations reflected in such forward‐looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements. These forward‐looking statements are subject to a number of risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the SEC. These forward‐looking statements speak only as of the date of this presentation and the Company undertakes no obligation to revise or update any forward‐looking statements to reflect events or circumstances after the date hereof. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market shares and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products. 2

Statins PCSK9i Ezetimibe Fish oils Statins Canakinumab GEMCABENE Gemcabene - Potential for Many Cardiometabolic Diseases SHTG / FCS / FPL Hypertriglyceridemia Inflammation Hypercholesterolemia Once Daily Tablet Observed to be a Safe “Add-On” to Statins and Other Lipid-Lowering Therapies in Trials to Date ~22M Patients ADDRESSABLE MARKET 3

A decrease in CRP (an earlier clinical assay) correlates with a decrease in hsCRP (the current CV risk assay). Gemcabene Differentiated Product Profile Multiple Important Cardiometabolic Benefits to Patients Observed 4 Significant Efficacy No Drug-Drug Interactions • LDL-C ~12-40% ↓ • TG ~20-50% ↓ • hsCRP ~25-50% ↓ Percentages (Mean and Median - LDL-C, Median - hsCRP, TG) have been demonstrated across multiple clinical studies in relevant patient populations • High dose atorvastatin • High dose simvastatin • Digoxin • PCSK9 Inhibitors • Ezetimibe Extensive Clinical Program Promising Safety and Tolerability • > 1,110 subjects treated with gemcabene • 23 completed Ph1 and Ph2 clinical trials • Multiple cardiometabolic indications studied, including: • Severe Hypertriglyceridemia • ASCVD • Hypercholesterolemia • Familial Partial Lipodystrophy • No myalgia as monotherapy • No liver toxicities • No significant affect on kidney function • No QTc prolongation • No clinically meaningful change in blood pressure • No food effect

Addressing the FDA Partial Clinical Hold • Completing ongoing clinical trials of up to 6 months as allowed on partial clinical hold • Hired additional regulatory & toxicology consultants to efficiently execute our plans • In vitro PPAR-a transactivation study in dog and monkey is completed, per FDA request • Initiated CRO-related activities to conduct 13 week PPAR-a knockout mouse study, requested by FDA • Submission of request to lift partial clinical hold to the FDA expected to occur in Q4’19 5

Major Milestones for 2019 • Top-line clinical results from Phase 2 Familial Partial Lipodystrophy (FPL)/NASH trial (expected Q2) • Submit preclinical toxicology report to FDA to address partial clinical hold (expected Q4) • Conducting a review of a range of strategic alternatives with Ladenburg Thalmann as the strategic financial advisor, focused on maximizing stockholder value 6

Gemcabene for Cardiometabolic Diseases Orphan Indications (>$500M Market) • Familial Chylomicronemia Syndrome (FCS) • Familial Partial Lipodystrophy (FPL) • Homozygous Familial Hypercholesterolemia (HoFH) Broader Populations (>$5B Market) • Severe Hypertriglyceridemia (SHTG) (TG ≥ 500 mg/dL) • Heterozygous FH (HeFH) and ASCVD • Mixed Dyslipidemia • NAFLD/NASH 7 Potential for Value Creation in Both Rare and Broad Cardiometabolic Patient Populations Staged approach to multiple markets –“Orphan-First Strategy”

Rationale for “Orphan-First” Strategy • Large unmet clinical need: FCS, FPL, and HoFH are considered orphan diseases and current therapies are inadequate • Smaller, less expensive trials: Historically, these trials enroll fewer patients and FDA approvals have been based on surrogate endpoints (e.g., serum LDL-C or TGs) • Potential rapid path to market: If approved, pursue rapid market entry with a targeted sales force addressing the most severe segment of dyslipidemia at an appropriate price point • Future potential to address much larger markets: If approved, build on gemcabene’s orphan branding to seek FDA approval for broader indications, such as SHTG and potentially ASCVD and NASH 8

Hypertriglyceridemia Opportunity Orphan • Familial Partial Lipodystrophy (FPL) – 300 Pts, TGs >250 with other metabolic anomalies • Familial Chylomicronemia Syndrome (FCS)- 1K Pts, TGs >750 mg/dL Broader Indications (Future) • Severe Hypertriglyceridemia (SHTG) – 3M Pts, TGs ≥500 mg/dL • ~60-70M Patients with highly elevated TGs ≥150 mg/dL Orphan Indications to Broad Indications Sarwar N et al. Circulation. 2007;115:450-8; Christian et al. American Journal of Cardiology 2011: 107:891 CVRG; Trends in Elevated Triglyceride in Adults: United States, 2001–2012, NCHS Data Brief No. 198, May 2015; The National Organization for Rare Disease (https://rarediseases.org/); Cardiovascular Research Group (CVRG) 2018 Orphan Opportunity Gemcabene has potential to address large unmet need for patients facing morbidity and mortality concerns Broader Market Opportunity Recent trials by others suggest lowering TGs and inflammation improves outcomes (MACE) 9

Recent News in Triglyceride Market 10

Primary Endpoint: % Change in Serum TGs 0 100 200 300 400 500 600 700 Placebo n=31 Gemcabene 300 mg n=30 Gemcabene 600 mg n=30 Median Plasma Triglycerides (mg/dL) Baseline End of Study *p=0.0063 n.s. *p-value based on Ranked ANCOVA Significant Decrease in TGs Observed with Gemcabene 600 mg in INDIGO-1 Trial of Severe Hypertriglyceridemia (SHTG) 47% End of Study = Average of Week 10 and Week 1211

Limitations of Current TG Therapies Competitor Limitations • Food Effect & Compliance – Prescription fish oil (i.e., EPA): 4g/day (4-8 capsules/day) taken multiple times during the day, GI discomfort • Safety – Fibrates: Most used but product label contraindicates with statins; liver enzyme and LDL-C elevations – Niacin: Hepatotoxicity, tolerability flushing/itching/rash, may increase blood glucose level • Lack of Efficacy – OTC fish oil • Statin Add-on Needed – Statins are widely used but a safe add- on therapeutic is often needed Disadvantages of Fish Oils, Fibrates, Niacin *Includes all indications; 2017 estimates from DRG Market Forecast Assumptions-Dyslipidemia (2016-2026)-September 2017 and NHIS Use of Complementary Health Approaches in the U.S., 2017 TG Lowering Agent Treated Patients* 2017 Estimates Fibrates 3.8M patients/year Fish Oils (Rx) 810K patients/year Fish Oils (OTC) 18M patients/year Niacin 375K patients/year LARGE EXISTING MARKET DESPITE LIMITATIONS OF FIBRATES, FISH OILS & NIACIN 12

Familial Chylomicronemia Syndrome (FCS) 13 Gemcabene has potential to benefit patients with life-threatening disease • A rare disease caused by genetic mutation(s) of the lipoprotein lipase (LPL) complex, leading to a massive accumulation of chylomicrons in the blood • Diagnosis based on fasting triglyceride levels >750 mg/dL • Patients often experience recurrent abdominal pain and/or pancreatitis • FCS represents ~3000-5000 patients worldwide (~1000 in the US) • There are currently no FDA-approved treatments for FCS • There is a high unmet need for effective TG-lowering therapies for FCS patients The National Pancreas Foundation (https://pancreasfoundation.org/); Cardiovascular Research Group (CVRG) 2018 Gemcabene’s meaningful safety, tolerability, and broad ranging efficacy in prior studies has the potential to benefit a host of cardiometabolic patients, including those with FCS

Gemcabene Opportunity in FCS • Gemcabene has shown efficacy to lower TGs in multiple Phase 2 trials, including patients with TGs >750 mg/dL • Prior FCS trials had an approvable endpoint of lowering TGs – no outcome trial was needed • KOLs express need for a drug to safely and effectively treat FCS patients for TG reduction • Potential for Orphan Designation • No FDA approved products on market today 14 Efficient clinical trial path with no approved drugs on market

Familial Partial Lipodystrophy (FPL) 15 Significant potential for gemcabene to demonstrate effects on established measures of FPL • FPL is a rare genetic disorder and orphan disease characterized by an inability to store fat correctly, leading to a buildup of fat around all vital organs and in the blood • FPL can lead to loss of metabolic control and these patients present with a variety of metabolic abnormalities, including diabetes, hypertriglyceridemia, hypercholesterolemia, premature cardiovascular disease, hyperphagia, and NASH • The prevalence of FPL is estimated to be 1 in 1,000,000 in US • Many patients are statin intolerant and use polypharmacy for their diabetes and lipid abnormalities with inadequate results The National Organization for Rare Disease (https://rarediseases.org/rare-diseases/familial-partial-lipodystrophy/)

Gemcabene Opportunity in FPL • Enrollment completed for Phase 2 open-label, 24 week trial in FPL patients - investigator initiated study at the Univ. of Michigan • Top-line Phase 2 data, including TG reduction and MRI- PDFF, expected in Q2’19 • To date, no safety signals • Prior Phase 3 FPL trials recruited ~ 60 patients across well established centers of excellence • Potential for Orphan Designation • Current investigational therapies have observed toxicity issues 16

Exploring Regional Gemcabene Opportunities - China • Recent regulatory changes in China favor US-China partnering, offering potentially faster regulatory times and preferences for innovative medications • China ranks among the highest in prevalence of hypercholesterolemia and hypertriglyceridemia in the world – China has highest prevalence of hypertriglyceridemia (>200M pts) – HoFH in China is an significant unmet need and a larger population compared to the US – Heightened sensitivity to statins in the Asian population • Gemphire is exploring regional partnering opportunities in China and will evaluate the feasibility for clinical collaborations 17

Gemcabene’s Novel Mechanisms of Action Lowered LDL-C, TGs, ApoCIII, ApoB & hsCRP in Prior Trials Additive to Statin MOA Not shown above, hsCRP is reduced via inhibition of gene transcription via blocking c/EBP binding REDUCED PRODUCTION • Inhibits de novo synthesis of TGs and cholesterol in the liver • TG effects due to inhibition of acetyl CoA carboxylase 1 • ↓VLDL-C particles leaves fewer apolipoproteins for catabolism to LDL-C IMPROVED CLEARANCE • Reduces ApoC-III gene expression and plasma ApoC-III protein levels • Enhances VLDL-C clearance through increased affinity for the hepatic remnant receptor 18

TG’s>500 Method Patent (Expires Sep 2032) Method Patents (Allowed patent expires Jan 2033; Others pending) Method Patent (Expires Nov 2036) Method Patent Application (If granted Expires Feb 2037) Patent Protection for Gemcabene IP Protection for Indications and Long-Term Runway for Commercialization 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 Protection by Year by Indication (US Market) COM = Composition of Matter Potential Pediatric Estimated FDA Approval Expiry Date COM FH SHTG NASH ASCVD POTENTIAL FOR REGULATORY EXCLUSIVITY FOR A NEW CHEMICAL ENTITY (NCE) US (5 years); US Orphan (FH) (7 years); Europe NCE or Orphan (10 years), Japan NCE (about 8 years); Japan Orphan (about 10 years); China (6 years); China Orphan (10 years)19

Prior Marketed Products Experience Proven and Successful Management Team Steve Gullans, PhD, FAHA Chief Executive Officer Charles Bisgaier, PhD Chief Scientific Officer & Cofounder Seth Reno, MBA Chief Commercial Officer Rebecca Bakker-Arkema, RPh, MS, FAHA VP, Drug & Clinical Development Prior Pipeline Development Experience ETC-1002 and ETC-216 (Esperion) PNT-2258 (ProNAi) ACP-501 (AstraZeneca/AlphaCore) 20

John Kastelein, MD, PhD Amsterdam, Netherlands Evan Stein, MD, PhD Illinois, USA Rob Hegele, MD Toronto, Canada Harold Bays, MD Kentucky, USA Rohit Loomba, MD California, USA Key Opinion Leaders Involved in Cardiometabolic Drug Development Clinical Advisors 21

Gemphire Capitalization and Coverage NASDAQ GLOBAL MARKET Symbol GEMP Market Cap1 ~$11.6M Price Per Share1 $0.81/share Shares Outstanding2 14.3M Cash at 9/30/18 $23.8M Institutional Ownership Shares Held3 Venrock 1,383K shares (10%) BlackRock 675K shares (5%) Excel Venture Management 930K shares (7%) NorthPointe Capital, LLC 482K shares (3%) Pfizer 675K shares (5%) The Vanguard Group, Inc. 382K shares (3%) GEMP Analyst Coverage CANACCORD GENUITY INC. John Newman, Ph.D. RAYMOND JAMES & ASSOCIATES Laura Chico, Ph.D. JEFFERIES LLC Matthew J. Andrews* LAIDLAW & COMPANY Frank Brisebois LIFESCI CAPITAL Patrick Dolezal PIPER JAFFRAY & CO Charles Duncan, Ph.D.* ROTH CAPITAL PARTNERS Yasmeen Rahimi, Ph.D. 1. At 1/3/19 2. At 9/30/18, Fully Diluted Shares Outstanding = 18.1M; 3. Shares Held at 9/30/18 or most recent reported shares (Percentage Ownership Calculated on Shares Outstanding at 9/30/18) * New coverage assignment pending 22

APPENDIX 23

Gemcabene Opportunity in SHTG • Once-daily, oral pill • No observed food effect, unlike fish oils • Safety and tolerability in >1100 trial subjects • Observed to safely combine with statins and other drugs • Serum TG has been an FDA approvable endpoint for patients with TGs ≥500 mg/dL; with no outcome trial required; same path used for Vascepa™, gemfibrozil and fenofibrate • Issued US and Worldwide method patents valid into 2032 Product Profile and Path to Market Gemcabene’s promising safety, tolerability, and broad ranging efficacy in prior studies has the potential to benefit a host of cardiometabolic patients, including those with SHTG 24

REDUCTION OF RESIDUAL RISK FACTORS Including: Cholesterol-Rich VLDL-Remnants and Inflammation Despite marked advances in LDL lowering, people still die from CV disease Risk Factors High LDL-C Residual Risk Triglycerides Inflammation ApoB Atherogenic Particles LDL-C Lowering Therapies: • Statins: 25-35% Relative Risk Reduction (RRR) • Ezetimibe: 6% RRR • PCSK9 Inhibitors: 15% RRR Therapies Addressing Residual Risk Factors (Recent CVOTs): • Triglycerides: Vascepa (Pure EPA Omega-3): 25% RRR • Inflammation: Canakinumab: 15% RRR Contributors to Residual Risk: • TG-rich remnant particles, small very-low-density lipoprotein or intermediate-density lipoprotein (pro-atherogenic, pro- inflammatory, pro-thrombotic effects) Gemcabene May Address Residual CV Risk by Lowering LDL-C, TG, and hsCRP Ganda, O.P. et al. J Am Coll Cardiol. 2018;72(3):330–43; company presentations 25-35% CV Risk 65-75% 25

Absolute Levels of TGs In INDIGO-1 538 mg/dL 333 mg/dL 200 300 400 500 600 700 Baseline Week 2 Week 6 Week 10 End of Study Median Plasma Triglycerides (mg/dL) Median Plasma Triglycerides Placebo Gemcabene 600 mg Lower TG level in the 600 mg Group vs Placebo at End of Study p=0.0137* *Ranked ANCOVA p-value for the placebo-adjusted difference of 600 mg vs placebo 26

300 400 500 600 700 800 Baseline End of Study Median Plasma Triglycerides (mg/dL) Placebo- INDIGO Gemcabene 600 mg- INDIGO Vascepa 4g- MARINE Vascepa 2g- MARINE Placebo- MARINE Gemcabene (Indigo) Compared to Vascepa (Marine) Treatment Goal for SHTG is TGs <500 mg/dL American Journal of Cardiology 2003;92:538–543; American Journal of Cardiology 2011; 108:682–690 27

-30% -28% -38% -61% -28% -43% -27% -48% -37% -70% -60% -50% -40% -30% -20% -10% 0% Median % Change from Placebo at EOS Gemcabene 600 mg ** * * * n=14 n=14 n=14 n=14 n=14 n=14 n=14 n=14 n=14 Lipid and Inflammatory Marker Reductions Observed in INDIGO-1 Gemcabene Reduces Atherogenic and Inflammatory Markers that May Reduce Residual Risk in Patients^ * Ranked ANCOVA p<0.05 ^Subset of patients from INDIGO-1 trial with LDL-C ≥100 mg/dL and TGs ≥ 200 mg/dL Atherogenic Markers Inflammatory 28

29 Gemcabene Appears to Upregulate VLDL-receptor (Syndecan-1 receptor) via Inhibition of Sulfatase II Gemcabene, which has been shown to lower plasma ApoB-lipoprotein concentrations in mice and human trials, appears to regulate remnant receptor via SULF2 in the liver